Opko Health Financials
Opko Health (OPK) reported $606.9M in revenue for fiscal year 2025, down 14.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Overhead cuts are narrowing losses, but persistent operating cash burn shows the business still is not self-funding.
Liquidity improved as the current ratio moved from 3.4x to 4.0x. But cash conversion stayed weak, with operating cash flow still near-$179M , so the added flexibility is coming from the balance sheet rather than the business funding itself.
Even with sales pressure, operating losses narrowed because SG&A fell to
This is a low-debt but cash-consuming setup: long-term debt was only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Opko Health's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Opko Health has an operating margin of -19.4%, meaning the company loses $19 on every $100 of revenue. This results in a profitability score of 27/100. This is up from -21.3% the prior year.
Opko Health's revenue declined 14.9% year-over-year, from $713.1M to $606.9M. This contraction results in a growth score of 7/100.
Opko Health carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.97, Opko Health holds $3.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 85/100.
Opko Health's operations used $178.5M of cash, and capex of $12.3M added to the outflow, for a free cash flow shortfall of $190.8M. This results in a cash flow score of 11/100.
Opko Health scores -0.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($664.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Opko Health passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Opko Health generated $606.9M in revenue in fiscal year 2025. This represents a decrease of 14.9% from the prior year.
Opko Health's EBITDA was -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.2% from the prior year.
Opko Health earned -$0.30 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 275.0% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Opko Health recorded an outflow of $190.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 8.5% from the prior year.
Opko Health held $364.4M in cash against $2.3M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Opko Health's gross margin was 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.
Opko Health's operating margin was -19.4% in fiscal year 2025, reflecting core business profitability. This is up 2.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Opko Health invested $124.0M in research and development in fiscal year 2025. This represents an increase of 17.9% from the prior year.
Opko Health spent $47.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 47.9% from the prior year.
Opko Health invested $12.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.9% from the prior year.
OPK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $587.9M | $606.9M-14.9% | $713.1M-17.4% | $863.5M-14.0% | $1.0B-43.4% | $1.8B+23.6% | $1.4B+59.1% | $901.9M-8.9% | $990.3M+2.5% | $966.0M-13.6% | $1.1B+266.0% | $305.3M+235.0% | $91.1M-5.6% | $96.5M+105.2% | $47.0M+68.1% | $28.0M |
| Cost of Revenue | N/A | $400.9M-18.9% | $494.6M-9.3% | $545.4M-23.8% | $716.0M | N/A | N/A | N/A | N/A | $61.2M-89.2% | $564.1M+191.8% | $193.3M+1962.6% | $9.4M-10.0% | $10.4M-62.6% | $27.9M+61.7% | $17.2M |
| Gross Profit | N/A | $205.9M-5.8% | $218.5M-31.3% | $318.1M+10.4% | $288.2M | N/A | N/A | N/A | N/A | $904.8M+63.5% | $553.4M+394.1% | $112.0M+37.0% | $81.8M-5.1% | $86.1M+349.3% | $19.2M+78.5% | $10.7M |
| R&D Expenses | N/A | $124.0M+17.9% | $105.2M+17.4% | $89.6M+21.3% | $73.9M-3.9% | $76.8M+2.0% | $75.3M-36.1% | $117.9M-6.1% | $125.6M-0.7% | $126.4M+11.0% | $113.9M+11.9% | $101.8M+21.8% | $83.6M+55.0% | $53.9M+176.1% | $19.5M+72.0% | $11.4M |
| SG&A Expenses | N/A | $223.0M-26.7% | $304.2M+1.2% | $300.6M-19.4% | $372.7M-20.5% | $468.9M+31.9% | $355.6M+3.6% | $343.3M-4.2% | $358.3M-13.6% | $414.6M+1.8% | $407.3M+136.6% | $172.1M+197.1% | $57.9M+4.7% | $55.3M+99.0% | $27.8M+45.0% | $19.2M |
| Operating Income | N/A | -$117.4M+22.8% | -$152.1M+3.2% | -$157.0M+30.6% | -$226.3M-1306.7% | $18.8M-67.5% | $57.7M+121.1% | -$274.1M-60.1% | -$171.2M+38.1% | -$276.4M-186.3% | -$96.6M+19.9% | -$120.6M+17.3% | -$145.8M-83.1% | -$79.6M-113.7% | -$37.3M-60.7% | -$23.2M |
| Interest Expense | N/A | $0-100.0% | $47.5M+251.4% | $13.5M+12.0% | $12.1M-36.1% | $18.9M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.0M |
| Income Tax | N/A | -$15.7M-136.7% | $42.8M+865.6% | $4.4M+107.0% | -$63.5M-510.0% | $15.5M-12.1% | $17.6M+149.5% | $7.1M+118.2% | -$38.7M-305.4% | $18.9M+133.6% | -$56.1M+50.6% | -$113.7M-473745.8% | $24K-98.6% | $1.7M+117.4% | -$9.6M+50.3% | -$19.4M |
| Net Income | -$72.9M | N/A | N/A | N/A | N/A | N/A | $30.6M+109.7% | -$314.9M-105.8% | -$153.0M+49.9% | -$305.3M-531.2% | -$48.4M+7.2% | -$52.1M+69.6% | -$171.7M-50.0% | -$114.4M-293.9% | -$29.0M-2164.1% | -$1.3M |
| EPS (Diluted) | -$0.09 | -$0.30-275.0% | -$0.08+68.0% | -$0.25+45.7% | -$0.46-820.0% | -$0.05-200.0% | $0.05+109.4% | -$0.53-96.3% | -$0.27+50.9% | -$0.55-450.0% | -$0.10+9.1% | -$0.11 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OPK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9B-12.2% | $2.2B+9.4% | $2.0B-7.2% | $2.2B-9.7% | $2.4B-3.0% | $2.5B+7.1% | $2.3B-5.8% | $2.5B-5.4% | $2.6B-6.4% | $2.8B-1.2% | $2.8B+120.8% | $1.3B-8.9% | $1.4B+380.1% | $289.8M+26.3% | $229.5M |
| Current Assets | $581.9M-12.1% | $662.1M+113.9% | $309.5M-21.6% | $394.5M-52.1% | $823.0M+57.3% | $523.2M+61.5% | $324.0M+2.0% | $317.7M-8.9% | $348.9M-27.9% | $483.6M+6.5% | $454.1M+217.8% | $142.9M-41.1% | $242.7M+208.6% | $78.7M-21.0% | $99.6M |
| Cash & Equivalents | $364.4M-14.6% | $426.6M+344.9% | $95.9M-37.4% | $153.2M+13.7% | $134.7M+86.6% | $72.2M-15.5% | $85.5M-11.4% | $96.5M+5.4% | $91.5M-45.8% | $168.7M-12.8% | $193.6M+99.8% | $96.9M-47.8% | $185.8M+579.1% | $27.4M-61.7% | $71.5M |
| Inventory | $65.8M+15.9% | $56.8M-13.5% | $65.7M-11.3% | $74.1M-14.4% | $86.5M-34.6% | $132.3M+147.7% | $53.4M+26.3% | $42.3M-14.3% | $49.3M+4.5% | $47.2M+19.0% | $39.7M+139.0% | $16.6M-8.2% | $18.1M-18.8% | $22.3M+66.9% | $13.3M |
| Accounts Receivable | $90.3M-23.5% | $118.0M-4.3% | $123.4M-3.1% | $127.3M-51.0% | $259.6M-9.3% | $286.3M+112.7% | $134.6M-6.5% | $143.9M-13.1% | $165.5M-24.9% | $220.3M+13.6% | $193.9M+870.9% | $20.0M+1.0% | $19.8M-6.6% | $21.2M+68.7% | $12.5M |
| Goodwill | $484.3M-8.5% | $529.3M-11.5% | $598.3M+0.4% | $595.9M+14.5% | $520.6M-23.5% | $680.6M+1.3% | $671.9M-4.0% | $700.2M-2.4% | $717.1M+1.8% | $704.6M-5.2% | $743.3M+231.4% | $224.3M-0.9% | $226.4M+181.4% | $80.5M+102.1% | $39.8M |
| Total Liabilities | $664.0M-20.5% | $834.8M+34.1% | $622.5M+2.8% | $605.6M-15.3% | $714.6M-10.8% | $801.5M+15.4% | $694.5M+5.3% | $659.8M-11.6% | $746.3M+3.6% | $720.2M-12.1% | $819.4M+89.7% | $431.9M-16.7% | $518.5M+499.1% | $86.5M+95.7% | $44.2M |
| Current Liabilities | $146.7M-24.0% | $193.1M-3.5% | $200.1M-6.3% | $213.5M-35.3% | $330.0M-12.1% | $375.5M+50.7% | $249.1M-13.6% | $288.3M-7.6% | $312.0M+30.0% | $240.0M-4.7% | $251.9M+203.1% | $83.1M-9.5% | $91.8M+75.3% | $52.4M+179.0% | $18.8M |
| Long-Term Debt | $2.3M-24.7% | $3.0M-61.1% | $7.7M-16.8% | $9.3M-95.5% | $205.3M+5249.8% | $3.8M-1.8% | $3.9M-16.1% | $4.7M+197.0% | $1.6M+118.5% | $717K-71.6% | $2.5M+3.7% | $2.4M-25.6% | $3.3M-36.5% | $5.2M | N/A |
| Total Equity | $1.3B-7.1% | $1.4B-1.7% | $1.4B-11.0% | $1.6B-7.3% | $1.7B+0.8% | $1.7B+3.5% | $1.6B-9.9% | $1.8B-2.8% | $1.8B-9.9% | $2.0B+2.3% | $2.0B+137.5% | $842.1M-3.9% | $876.4M+388.6% | $179.4M+11.5% | $160.9M |
| Retained Earnings | -$2.3B-10.9% | -$2.1B-2.6% | -$2.0B-10.4% | -$1.8B-20.6% | -$1.5B-2.0% | -$1.5B+1.9% | -$1.5B-26.2% | -$1.2B-14.1% | -$1.0B-35.3% | -$775.3M-10.0% | -$704.9M-4.4% | -$674.8M-34.1% | -$503.2M-29.4% | -$388.8M-8.1% | -$359.7M |
OPK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$123.4M | -$178.5M+2.7% | -$183.5M-550.7% | -$28.2M+70.4% | -$95.2M-348.3% | $38.3M-2.9% | $39.5M+122.9% | -$172.5M-58.1% | -$109.1M-18.5% | -$92.1M-387.3% | $32.0M-80.5% | $164.0M+281.5% | -$90.4M-62.4% | -$55.7M-119.0% | -$25.4M-37.4% | -$18.5M |
| Capital Expenditures | $10.6M | $12.3M-50.9% | $25.0M+53.7% | $16.3M-33.8% | $24.6M-23.6% | $32.2M-4.5% | $33.7M+164.4% | $12.7M-54.3% | $27.9M-40.1% | $46.5M+150.8% | $18.5M+71.0% | $10.8M+129.1% | $4.7M+19.5% | $4.0M+169.2% | $1.5M-24.6% | $2.0M |
| Free Cash Flow | -$134.0M | -$190.8M+8.5% | -$208.5M-368.8% | -$44.5M+62.9% | -$119.8M-2037.7% | $6.2M+6.7% | $5.8M+103.1% | -$185.3M-35.2% | -$137.0M+1.2% | -$138.6M-1126.8% | $13.5M-91.2% | $153.2M+261.0% | -$95.1M-59.5% | -$59.6M-121.7% | -$26.9M-31.5% | -$20.5M |
| Investing Cash Flow | $206.3M | $230.3M-34.6% | $352.2M+2035.5% | -$18.2M-120.0% | $91.0M+153.2% | $35.9M+296.2% | -$18.3M-38.1% | -$13.3M+49.2% | -$26.1M+44.0% | -$46.7M-125.4% | -$20.7M+79.1% | -$99.2M-1648.4% | -$5.7M-118.7% | $30.3M+222.4% | -$24.8M-67.0% | -$14.8M |
| Financing Cash Flow | -$52.7M | -$118.1M-164.1% | $184.2M+1729.4% | -$11.3M-149.2% | $23.0M+321.9% | -$10.3M+70.5% | -$35.1M-120.0% | $175.2M+24.4% | $140.9M+130.8% | $61.0M+273.4% | -$35.2M-206.6% | $33.0M+354.4% | $7.3M-96.0% | $183.6M+2944.9% | $6.0M-93.1% | $86.9M |
| Share Buybacks | $46.6M | $47.0M-47.9% | $90.2M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $7.8M |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OPK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.9%+3.3pp | 30.6%-6.2pp | 36.8%+8.1pp | 28.7% | N/A | N/A | N/A | N/A | 93.7%+44.1pp | 49.5%+12.8pp | 36.7%-53.0pp | 89.7%+0.5pp | 89.2%+48.5pp | 40.7%+2.4pp | 38.4% |
| Operating Margin | -19.4%+2.0pp | -21.3%-3.1pp | -18.2%+4.4pp | -22.5%-23.6pp | 1.1%-3.0pp | 4.0%+34.4pp | -30.4%-13.1pp | -17.3%+11.3pp | -28.6%-20.0pp | -8.6%+30.9pp | -39.5% | -160.0% | -82.5%-3.3pp | -79.2%+3.7pp | -82.9% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 2.1%+37.0pp | -34.9%-19.5pp | -15.4%+16.2pp | -31.6%-27.3pp | -4.3%+12.7pp | -17.1% | -188.4% | -118.5% | -61.8%-57.2pp | -4.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | 1.8%+21.3pp | -19.5%-11.0pp | -8.5%+8.0pp | -16.6%-14.2pp | -2.4%+0.3pp | -2.6%+17.8pp | -20.4%-7.3pp | -13.1%+3.1pp | -16.2%-15.4pp | -0.8% |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | 1.2%+14.9pp | -13.6%-7.4pp | -6.2%+5.6pp | -11.8%-10.0pp | -1.8%+0.1pp | -1.9%+11.7pp | -13.5%-5.3pp | -8.2%+1.8pp | -10.0%-9.5pp | -0.6% |
| Current Ratio | 3.97+0.5x | 3.43+1.9x | 1.55-0.3x | 1.85-0.6x | 2.49+1.1x | 1.39+0.1x | 1.30+0.2x | 1.100.0x | 1.12-0.9x | 2.01+0.2x | 1.80+0.1x | 1.72-0.9x | 2.64+1.1x | 1.50-3.8x | 5.30 |
| Debt-to-Equity | 0.000.0x | 0.000.0x | 0.010.0x | 0.01-0.1x | 0.12+0.1x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.03-0.2x | 0.27 |
| FCF Margin | -31.4%-2.2pp | -29.2%-24.1pp | -5.1%+6.8pp | -11.9%-12.3pp | 0.4%-0.1pp | 0.4%+20.9pp | -20.5%-6.7pp | -13.8%+0.5pp | -14.3%-15.6pp | 1.2%-49.0pp | 50.2% | -104.4% | -61.8%-4.6pp | -57.1%+15.9pp | -73.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Opko Health Ranks
Frequently Asked Questions
What is Opko Health's annual revenue?
Opko Health (OPK) reported $606.9M in total revenue for fiscal year 2025. This represents a -14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Opko Health's revenue growing?
Opko Health (OPK) revenue declined by 14.9% year-over-year, from $713.1M to $606.9M in fiscal year 2025.
What is Opko Health's EBITDA?
Opko Health (OPK) had EBITDA of -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Opko Health have?
As of fiscal year 2025, Opko Health (OPK) had $364.4M in cash and equivalents against $2.3M in long-term debt.
What is Opko Health's gross margin?
Opko Health (OPK) had a gross margin of 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Opko Health's operating margin?
Opko Health (OPK) had an operating margin of -19.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Opko Health's free cash flow?
Opko Health (OPK) recorded an outflow of $190.8M in free cash flow during fiscal year 2025. This represents a 8.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Opko Health's operating cash flow?
Opko Health (OPK) recorded an outflow of $178.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Opko Health's total assets?
Opko Health (OPK) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Opko Health's capital expenditures?
Opko Health (OPK) invested $12.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Opko Health spend on research and development?
Opko Health (OPK) invested $124.0M in research and development during fiscal year 2025.
What is Opko Health's current ratio?
Opko Health (OPK) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.
What is Opko Health's debt-to-equity ratio?
Opko Health (OPK) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Opko Health's cash runway?
Based on fiscal year 2025 data, Opko Health (OPK) had $364.4M in cash against an annual operating cash burn of $178.5M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Opko Health's Altman Z-Score?
Opko Health (OPK) has an Altman Z-Score of -0.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Opko Health's Piotroski F-Score?
Opko Health (OPK) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Opko Health?
Opko Health (OPK) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.